{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:28:24Z","timestamp":1790947704190,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ILiAD Biotechnologies, Weston, Florida, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pertussis remains a major public health challenge due to the inability of current acellular vaccines to prevent\n                    <jats:italic>Bordetella pertussis<\/jats:italic>\n                    colonisation and transmission. The live-attenuated intranasal vaccine, BPZE1, has shown efficacy in protecting against infection following challenge with virulent\n                    <jats:italic>B. pertussis,<\/jats:italic>\n                    but the immune mechanisms underpinning this protective effect are poorly defined. In this study, we demonstrate that intranasal vaccination with BPZE1 induced circulating CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells of Th17 and Th22 effector phenotype. These responses correlated positively with BPZE1-induced secretory IgA (SIgA) responses, suggesting coordinated induction of mucosal immunity. Among BPZE1 recipients who developed breakthrough infection following virulent\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    challenge, higher vaccine-induced SIgA titres were significantly associated with reduced colonisation density. By contrast, BPZE1-induced serum IgA and IgG titres were not associated with reduced colonisation density. These findings identify a Th17\/Th22-SIgA immune axis as a feature of BPZE1 vaccination and support the hypothesis that BPZE1-induced SIgA may contribute to reduced\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    colonisation density in participants with virulent\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    breakthrough infection despite BPZE1 vaccination.\n                  <\/jats:p>","DOI":"10.1038\/s41541-026-01443-7","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:53:59Z","timestamp":1776545639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation"],"prefix":"10.1038","volume":"11","author":[{"given":"Alison R.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Gbesemete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyween","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muktar","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"Laver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Locht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S1473-3099(17)30390-0","volume":"17","author":"KHT Yeung","year":"2017","unstructured":"Yeung, K. H. T., Duclos, P., Nelson, E. A. S. & Hutubessy, R. C. W. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect. Dis. 17, 974\u2013980 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1080\/21645515.2015.1137402","volume":"12","author":"A Preston","year":"2016","unstructured":"Preston, A. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development. Hum. Vaccines Immunother. 12, 1274\u20131276 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1016\/j.vaccine.2017.11.055","volume":"36","author":"C Locht","year":"2018","unstructured":"Locht, C. Will we have new pertussis vaccines? Vaccine 36, 5460\u20135469 (2018).","journal-title":"Vaccine"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/infdis\/jit491","volume":"209","author":"DL Burns","year":"2014","unstructured":"Burns, D. L., Meade, B. D. & Messionnier, N. E. Pertussis resurgence: perspectives from the Working Group Meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J. Infect. Dis. 209, S32\u201335 (2014).","journal-title":"J. Infect. Dis."},{"key":"1443_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0382-8","volume":"13","author":"BM Althouse","year":"2015","unstructured":"Althouse, B. M. & Scarpino, S. V. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 13, 146 (2015).","journal-title":"BMC Med."},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl. Acad. Sci. USA 111, 787\u2013792 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/ciz840","volume":"71","author":"H de Graaf","year":"2020","unstructured":"de Graaf, H. et al. Controlled human infection with Bordetella pertussis induces asymptomatic, immunizing colonization. Clin. Infect. Dis. 2020 71, 403\u2013411 (2020).","journal-title":"Clin. Infect. Dis. 2020"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41385-018-0073-9","volume":"11","author":"L Solans","year":"2018","unstructured":"Solans, L. et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunol. 11, 1753\u20131762 (2018).","journal-title":"Mucosal Immunol."},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.4049\/jimmunol.1003765","volume":"186","author":"G Fedele","year":"2011","unstructured":"Fedele, G., Bianco, M., Debrie, A. S., Locht, C. & Ausiello, C. M. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1\/Th17 response. J. Immunol. 186, 5388\u20135396 (2011).","journal-title":"J. Immunol."},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1128\/CVI.00371-10","volume":"18","author":"CM Skerry","year":"2011","unstructured":"Skerry, C. M. & Mahon, B. P. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin. Vaccine Immunol. 18, 187\u2013193 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1473-3099(20)30274-7","volume":"20","author":"M Jahnmatz","year":"2020","unstructured":"Jahnmatz, M. et al. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect. Dis. 20, 1290\u20131301 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1443_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(22)02644-7","volume":"401","author":"C Keech","year":"2023","unstructured":"Keech, C. et al. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet 401, 843\u201355 (2023).","journal-title":"Lancet"},{"key":"1443_CR13","doi-asserted-by":"publisher","first-page":"101211","DOI":"10.1016\/j.lanmic.2025.101211","volume":"6","author":"D Gbesemete","year":"2025","unstructured":"Gbesemete, D. et al. Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. Lancet Microbe 6, 101211 (2025).","journal-title":"Lancet Microbe"},{"key":"1443_CR14","doi-asserted-by":"publisher","first-page":"e01301","DOI":"10.1128\/genomeA.01301-14","volume":"2","author":"MJ Bart","year":"2014","unstructured":"Bart, M. J. et al. Complete genome sequences of Bordetella pertussis isolates B1917 and B1920, representing two predominant global lineages. Genome Announc. 2, e01301\u201301314 (2014).","journal-title":"Genome Announc."},{"key":"1443_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101366","volume":"14","author":"V Corbi\u00e8re","year":"2023","unstructured":"Corbi\u00e8re, V. et al. A semi high-throughput whole blood-based flow cytometry assay to detect and monitor Bordetella pertussis-specific Th1, Th2 and Th17 responses. Front. Immunol. 14, 1101366 (2023).","journal-title":"Front. Immunol."},{"key":"1443_CR16","doi-asserted-by":"publisher","first-page":"e83449","DOI":"10.1371\/journal.pone.0083449","volume":"9","author":"R Thorstensson","year":"2014","unstructured":"Thorstensson, R. et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine-BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS ONE 9, e83449 (2014).","journal-title":"PLoS ONE"},{"key":"1443_CR17","doi-asserted-by":"crossref","unstructured":"de Graaf, H. et al. Safety, colonization kinetics, transmissibility and immune correlates of protection inhealthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1,controlled human infection study. Lancet Microbe, 7,101313 (2026).","DOI":"10.1016\/j.lanmic.2025.101313"},{"key":"1443_CR18","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1016\/j.vaccine.2010.08.017","volume":"28","author":"PF Feunou","year":"2010","unstructured":"Feunou, P. F., Kammoun, H., Debrie, A. S., Mielcarek, N. & Locht, C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28, 7047\u201353 (2010).","journal-title":"Vaccine"},{"key":"1443_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/infdis\/jix254","volume":"216","author":"C Locht","year":"2017","unstructured":"Locht, C. et al. Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection. J. Infect. Dis. 216, 117\u201324 (2017).","journal-title":"J. Infect. Dis."},{"key":"1443_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41385-021-00407-5","volume":"14","author":"L Borkner","year":"2021","unstructured":"Borkner, L., Curham, L. M., Wilk, M. M., Moran, B. & Mills, K. H. G. IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F+ neutrophils. Mucosal Immunol. 14, 1183\u20131202 (2021).","journal-title":"Mucosal Immunol."},{"key":"1443_CR21","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1172\/JCI121309","volume":"128","author":"R da Silva Antunes","year":"2018","unstructured":"da Silva Antunes, R. et al. Th1\/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. J. Clin. Invest. 128, 3853\u20133865 (2018).","journal-title":"J. Clin. Invest."},{"key":"1443_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/vaccines8020225","volume":"8","author":"EE Lambert","year":"2020","unstructured":"Lambert, E. E. et al. Uncovering distinct primary vaccination-dependent profiles in human Bordetella pertussis specific CD4+ T-cell responses using a novel whole blood assay. Vaccines 8, 225 (2020).","journal-title":"Vaccines"},{"key":"1443_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/mi.2016.59","volume":"9","author":"J Spencer","year":"2016","unstructured":"Spencer, J. & Sollid, L. M. The human intestinal B-cell response. Mucosal Immunol. 9, 1113\u20131124 (2016).","journal-title":"Mucosal Immunol."},{"key":"1443_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/mi.2016.28","volume":"1","author":"D Christensen","year":"2017","unstructured":"Christensen, D., Mortensen, R., Rosenkrands, I., Dietrich, J. & Andersen, P. Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 1, 260\u2013270 (2017).","journal-title":"Mucosal Immunol."},{"key":"1443_CR25","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.4049\/jimmunol.0900237","volume":"182","author":"Z Jaffar","year":"2009","unstructured":"Jaffar, Z., Ferrini, M. E., Herritt, L. A. & Roberts, K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J. Immunol. 182, 4507\u20134511 (2009).","journal-title":"J. Immunol."},{"key":"1443_CR26","doi-asserted-by":"publisher","first-page":"951107","DOI":"10.3389\/fimmu.2022.951107","volume":"13","author":"S Fang","year":"2022","unstructured":"Fang, S., Ju, D., Lin, Y. & Chen, W. The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. Front. Immunol. 13, 951107 (2022).","journal-title":"Front. Immunol."},{"key":"1443_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.11.001","volume":"80","author":"LS Dean","year":"2024","unstructured":"Dean, L. S. et al. I don\u2019t know about you, but I\u2019m feeling IL-22. Cytokine Growth Factor Rev. 80, 1\u201311 (2024).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1443_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2119\/molmed.2013.00115","volume":"20","author":"Y Peng","year":"2014","unstructured":"Peng, Y. et al. Interleukin-22 promotes T helper 1 (Th1)\/Th17 immunity in chlamydial lung infection. Mol. Med. 20, 109\u2013119 (2014).","journal-title":"Mol. Med."},{"key":"1443_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clim.2015.02.009","volume":"157","author":"WGH Han","year":"2015","unstructured":"Han, W. G. H., Helm, K., Poelen, M. M. C., Otten, H. G. & van Els, C. A. C. M. Ex vivo peptide-MHC II tetramer analysis reveals distinct end-differentiation patterns of human pertussis-specific CD4(+) T cells following clinical infection. Clin. Immunol. 157, 205\u2013215 (2015).","journal-title":"Clin. Immunol."},{"key":"1443_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1084\/jem.178.4.1309","volume":"178","author":"J Xu-Amano","year":"1993","unstructured":"Xu-Amano, J. et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178, 1309\u20131320 (1993).","journal-title":"J. Exp. Med."},{"key":"1443_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-101320-030339","volume":"40","author":"H Hammad","year":"2022","unstructured":"Hammad, H., Debeuf, N., Aegerter, H., Brown, A. S. & Lambrecht, B. N. Emerging paradigms in type 2 immunity. Annu. Rev. Immunol. 40, 443\u2013467 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"1443_CR32","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1016\/S0264-410X(03)00407-9","volume":"21","author":"J Storsaeter","year":"2003","unstructured":"Storsaeter, J., Hallander, H. O., Gustafsson, L. & Olin, P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21, 3542\u20133549 (2003).","journal-title":"Vaccine"},{"key":"1443_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/0264-410X(93)90286-7","volume":"11","author":"M Granstr\u00f6m","year":"1993","unstructured":"Granstr\u00f6m, M. & Granstr\u00f6m, G. Serological correlates in whooping cough. Vaccine 11, 445\u2013448 (1993).","journal-title":"Vaccine"},{"key":"1443_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0022-3476(05)82873-2","volume":"116","author":"G Zackrisson","year":"1990","unstructured":"Zackrisson, G., Taranger, J. & Trollfors, B. History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J. Pediatr. 116, 190\u2013194 (1990).","journal-title":"J. Pediatr."},{"key":"1443_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9258","volume":"6","author":"AW Nguyen","year":"2020","unstructured":"Nguyen, A. W. et al. Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons. Sci. Adv. 6, eaay9258 (2020).","journal-title":"Sci. Adv."},{"key":"1443_CR36","doi-asserted-by":"publisher","first-page":"e0133209","DOI":"10.1371\/journal.pone.0133209","volume":"10","author":"S Bolotin","year":"2015","unstructured":"Bolotin, S. et al. Correlation of real time PCR cycle threshold cut-off with Bordetella pertussis clinical severity. PLoS ONE 10, e0133209 (2015).","journal-title":"PLoS ONE"},{"key":"1443_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/INF.0000000000003471","volume":"41","author":"DT Thuy Nga","year":"2022","unstructured":"Thuy Nga, D. T. et al. Association between real-time polymerase chain reaction cycle threshold value and clinical severity in neonates and infants infected with Bordetella pertussis. Pediatr. Infect. Dis. J. 41, 388\u2013393 (2022).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1443_CR38","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1016\/S2666-5247(22)00283-X","volume":"3","author":"AP Dale","year":"2022","unstructured":"Dale, A. P. et al. Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial. Lancet Microbe 3, e931\u2013943 (2022).","journal-title":"Lancet Microbe"},{"key":"1443_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf809","volume":"13","author":"DF Gbesemete","year":"2026","unstructured":"Gbesemete, D. F. et al. Controlled human infection of healthy adults with lyophilized Neisseria lactamica induces asymptomatic, immunogenic nasopharyngeal carriage in the United Kingdom and Mali. Open. Forum Infect. Dis. 13, ofaf809 (2026).","journal-title":"Open. Forum Infect. Dis."},{"key":"1443_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1164\/rccm.201212-2277OC","volume":"187","author":"DM Ferreira","year":"2013","unstructured":"Ferreira, D. M. et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am. J. Respir. Crit. Care Med. 187, 855\u2013864 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1443_CR41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/infdis\/jit238","volume":"208","author":"PL Winokur","year":"2013","unstructured":"Winokur, P. L., Chaloner, K., Doern, G. V., Ferreira, J. & Apicella, M. A. Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae. J. Infect. Dis. 208, 728\u2013738 (2013).","journal-title":"J. Infect. Dis."},{"key":"1443_CR42","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.chom.2023.06.015","volume":"31","author":"R da Silva Antunes","year":"2023","unstructured":"da Silva Antunes, R. et al. T cell reactivity to Bordetella pertussis is highly diverse regardless of childhood vaccination. Cell. Host Microbe 31, 1404\u20131416 (2023).","journal-title":"Cell. Host Microbe"},{"key":"1443_CR43","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1093\/infdis\/jiae034","volume":"230","author":"KN McCarthy","year":"2024","unstructured":"McCarthy, K. N., Hone, S., McLoughlin, R. M. & Mills, K. H. G. IL-17 and IFN-\u03b3-producing respiratory tissue resident memory CD4T cells persist for decades in adults immunized as children with whole cell pertussis vaccines. J. Infect. Dis. 230, e518\u2013e523 (2024).","journal-title":"J. Infect. Dis."},{"key":"1443_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/mi.2012.117","volume":"6","author":"JM Warfel","year":"2013","unstructured":"Warfel, J. M. & Merkel, T. J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal. Immunol. 6, 787\u2013796 (2013).","journal-title":"Mucosal. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01443-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:03:11Z","timestamp":1781827391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01443-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01443-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G., S.N. and K.R. are employees and equity holders of ILiAD Biotechnologies. C.L. holds patents on the BPZE1 vaccine, which is licensed to ILiAD Biotechnologies, and reports consulting fees from and is an equity holder of ILiAD Biotechnologies. R.C.R., A.D. and J.R.L. received grant funding from ILiAD Biotechnologies paid to their institution to support the conduct of the original clinical trial (no personal payments). S.N.F. received grants\/contracts\/consulting fees paid to his institution (no personal payments) from ILiAD Biotechnologies, Pfizer, Sanofi, GSK, J&J, Merck, AstraZeneca, Valneva, Moderna, BioNTech, MSD and Medimmune. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}